Evidence map›Paper›PMID 36247262›Full record

ArticleAmerican journal of translational research2022

Stentless at ostium: a novel approach for treating ostial left anterior descending or left circumflex coronary artery lesions with drug-coated balloons.

Wen-Jie Lu, Liang Pan, Zhan-Ying Han, San-Cong Pan, Xi Wang, Ying-Guang Shan, Meng Peng, Xiao-Fei Qin, Guo-Ju Sun, Pei-Sheng Zhang and 2 more

Abstract read
In one paragraph

Article in American journal of translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Wen-Jie LuDepartment of Cardiovascular Medicine, The First Affiliated Hospital of Zhengzhou University Zhengzhou, China.
Liang PanDepartment of Cardiovascular Medicine, The First Affiliated Hospital of Zhengzhou University Zhengzhou, China.
Zhan-Ying HanDepartment of Cardiovascular Medicine, The First Affiliated Hospital of Zhengzhou University Zhengzhou, China.
San-Cong PanDepartment of Cardiology, Jincheng People's Hospital Jincheng, China.
Xi WangDepartment of Cardiovascular Medicine, The First Affiliated Hospital of Zhengzhou University Zhengzhou, China.
Ying-Guang ShanDepartment of Cardiovascular Medicine, The First Affiliated Hospital of Zhengzhou University Zhengzhou, China.
Meng PengDepartment of Cardiovascular Medicine, The First Affiliated Hospital of Zhengzhou University Zhengzhou, China.
Xiao-Fei QinDepartment of Cardiovascular Medicine, The First Affiliated Hospital of Zhengzhou University Zhengzhou, China.
Guo-Ju SunDepartment of Cardiovascular Medicine, The First Affiliated Hospital of Zhengzhou University Zhengzhou, China.
Pei-Sheng ZhangDepartment of Cardiology, The Fifth Affiliated Hospital of Zhengzhou University Zhengzhou, China.
Jian-Zeng DongDepartment of Cardiovascular Medicine, The First Affiliated Hospital of Zhengzhou University Zhengzhou, China.
Chun-Guang QiuDepartment of Cardiovascular Medicine, The First Affiliated Hospital of Zhengzhou University Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurrently, there is no optimal treatment strategy for ostial left anterior descending (LAD) or ostial left circumflex artery (LCx) lesions. This study explored effectiveness and safety of drug-coated balloons (DCB) in individuals presenting with ostial LAD or LCx lesions.

methodsA total of 137 patients with

resultsOf the participants, 58 were treated with DCB-only and 62 with hybrid strategy. Relative to the DCB-only group, patients in the hybrid group had longer target lesions (15.47 ± 10.08

conclusionsWith regards to safety and efficacy, the strategy of DCB as a standalone therapy was similar in comparison with the hybrid strategy of DCB + DES for ostial LAD and ostial LCx lesions. This approach might be effective and technically easy in treating ostial LAD and LCx diseases.

Indexed as

de novoDrug-coated balloonostial LADostial LCx

Identifiers

PMID36247262
PMCPMC9556460

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.